AbbVie (ABBV)
Develops immunology, neuroscience, oncology, and aesthetics products led by Skyrizi and Rinvoq.
Something off on this page? Send us feedback.
AbbVie sells prescription medicines, with its center of gravity shifting from Humira to Skyrizi and Rinvoq. Those newer immune-disease medicines now do the heavy lifting, while brain, migraine, cancer and cosmetic treatments broaden the base. The next handoff depends on turning costly experimental medicines into approved products before today's leaders lose protection.
Item facts: FY2025 · year ended Dec 31, 2025, from filings, earnings calls and company pages.
Judgment weights, not filed revenue
The band summarizes business focus and direction. ~ marks estimates.
10 in detail · 11 more below
Skyrizi
AbbVie's biggest medicine treats several chronic immune diseases. Sales grew about 24% year over year in Q2 2026; continued gains depend on health-plan access, reliable production and patent protection.
Competes with Tremfya (Johnson & Johnson) · Omvoh (Eli Lilly)
In plain English
Think of Skyrizi as one tool fitted to several jobs. It quiets a particular part of the immune system that can drive psoriasis, Crohn's disease and ulcerative colitis, letting AbbVie sell the same medicine across several large groups of patients.
Doctors prescribe it, health plans decide how easily patients can get it, and repeat doses keep revenue coming. Adding diseases and easier ways to take the medicine brings in more patients, while rival treatments Tremfya and Omvoh compete for those new patients.
Rinvoq
A once-daily pill for several immune diseases, Rinvoq grew about 24% year over year in Q2 2026. Its reach is widening, but serious safety warnings, patient monitoring and health-plan rules shape use.
Competes with Cibinqo (Pfizer) · Olumiant (Eli Lilly/Incyte)
In plain English
This one is a daily tablet rather than a lab-made antibody. Rinvoq turns down immune signals behind arthritis, severe eczema and bowel inflammation, so one product can serve several diseases and compete with both pills and injected medicines.
AbbVie earns when doctors write prescriptions and patients refill them. The convenience of a pill helps, but the medicine carries serious safety warnings: doctors must decide who is suitable, monitor them, and work through health-plan restrictions. Cibinqo and Olumiant chase overlapping patients.
Apogee Therapeutics pipeline
AbbVie paid $10.9B for long-lasting experimental immune medicines led by zumilokibart for severe eczema. There are no product sales yet; late-stage testing, approval and dependable manufacturing decide whether the purchase becomes a business.
Competes with Ebglyss (Eli Lilly) · Dupixent (Sanofi/Regeneron)
In plain English
Here AbbVie paid upfront for a possible successor, not for current sales. Apogee's lead medicine is being tested as a longer-lasting treatment for severe eczema, while another candidate targets respiratory disease. Both are still experimental.
The idea is fewer doses and better control for patients, followed by repeat sales if regulators approve the medicines. Until then, money flows outward to trial sites and manufacturers. Approved medicines Ebglyss and Dupixent already set the standard that Apogee must beat or match in a useful way.
Botox Therapeutic
Doctor-administered Botox treats migraine, muscle tightness, bladder problems and other nerve-related conditions. Q2 2026 sales rose about 12%; growth relies on specialist use, insurance payment, trained injectors and sterile supply.
Competes with Dysport (Ipsen/Galderma) · Xeomin (Merz)
In plain English
A familiar cosmetic name also does serious medical work. Carefully placed Botox injections calm overactive nerve signals, helping people with problems such as recurring migraine, stiff muscles and an overactive bladder.
Specialist clinics buy the medicine and administer it on a schedule; insurers often pay when the treatment is medically approved. That creates repeat orders tied to diagnosed patients and trained injectors. Dysport and Xeomin offer doctors similar toxin-based treatments, so coverage, results and reliable sterile production matter.
Vraylar
Vraylar is a daily pill used for schizophrenia, bipolar disorder and alongside antidepressants. Sales grew about 19% year over year in Q2 2026; staying power rests on results, side effects and regular refills.
Competes with Caplyta (Johnson & Johnson) · Rexulti (Otsuka/Lundbeck)
In plain English
For people living with serious mood or thought disorders, treatment is often a long routine rather than a one-time fix. Vraylar is a daily pill used across schizophrenia, bipolar disorder and depression when an antidepressant alone is not enough.
Each continuing prescription can become another refill, provided the medicine helps and its side effects remain manageable. Health plans influence access, and patients may switch among alternatives such as Caplyta and Rexulti. AbbVie sells Vraylar but pays the company that invented it, Gedeon Richter, a cut of those sales.
Ubrelvy and Qulipta/Aquipta
Two oral migraine medicines divide the job: Ubrelvy treats an attack, while Qulipta aims to prevent one. Together they made $2.307B in FY2025; health-plan access and whether people keep taking them drive the next leg.
Competes with Nurtec ODT (Pfizer) · Emgality (Eli Lilly)
In plain English
Two pills divide one job. Ubrelvy is taken when a migraine attack arrives; Qulipta, called Aquipta in some countries, is taken to prevent attacks. That gives AbbVie a place in both the emergency cupboard and the daily routine.
Doctors prescribe them and health plans decide access, while repeat use turns relief and prevention into sales. The field is crowded: Nurtec can cover both immediate and preventive use, and Emgality is a longer-acting injection. AbbVie must keep patients on treatment, not merely win the first prescription.
Humira
Once AbbVie's central product, Humira now competes with lower-cost, closely matched versions. Q2 2026 sales fell about 36%; its remaining job is to keep generating cash while newer immune medicines take over.
Competes with Amjevita (Amgen) · Cyltezo (Boehringer Ingelheim)
In plain English
The former center of AbbVie is now a shrinking but still meaningful business. Humira is a self-injected medicine for arthritis, psoriasis, bowel disease and other conditions caused by an overactive immune system.
Its patents no longer keep close copies out of the United States. Health plans can favor those alternatives, and lower prices and substitution steadily pull prescriptions away. Existing patients and contracts still produce sales, but Amjevita and Cyltezo are built to serve the same uses. Humira's role has changed from growth engine to cash-producing bridge.
Imbruvica
Imbruvica is a pill for certain blood cancers, but newer rivals are winning patients. Sales dropped about 29% year over year in Q2 2026, and AbbVie shares the medicine's U.S. profits with Janssen.
Competes with Calquence (AstraZeneca) · Brukinsa (BeOne Medicines)
In plain English
An early winner in blood-cancer pills is being overtaken. Imbruvica blocks a signal some cancer cells use to survive, and patients take it according to their disease and treatment plan. Newer medicines Calquence and Brukinsa now compete for many of the same people and have been gaining ground.
When the medicine sells, AbbVie does not keep all the money: Janssen controls sales outside the United States and the partners split U.S. profit and loss equally. Fewer new patients or shorter treatment therefore shrink both sales and the amount AbbVie ultimately keeps.
Venclexta/Venclyxto
Venclexta blocks a survival switch used by certain leukemia cells and remains AbbVie's growing cancer counterweight. Q2 2026 sales rose about 10%; treatment combinations and the profit-sharing deal determine what AbbVie keeps.
Competes with Lisaftoclax (Ascentage Pharma) · Calquence (AstraZeneca)
In plain English
Cancer cells can lean on an internal survival switch; Venclexta is a pill designed to block it. Doctors use the medicine for certain leukemias, sometimes alongside other treatments, and the length and mix of those treatment plans create demand.
AbbVie makes and distributes the drug, while Genentech and Roche share half of U.S. profit before tax. That means rising sales do not all stay with AbbVie. Lisaftoclax targets the same switch, while Calquence offers another route for some of the same leukemia patients.
Botox Cosmetic
Botox Cosmetic is the out-of-pocket side of the toxin franchise, sold through trained cosmetic injectors. Q2 2026 sales grew about 3%; demand is more exposed to consumer budgets and rival claims about duration.
Competes with Dysport (Ipsen/Galderma) · Xeomin (Merz) · Daxxify (Crown Laboratories/Revance)
In plain English
This side of Botox is bought for appearance rather than illness. Trained injectors use small doses in facial-aesthetic procedures, and customers usually pay out of pocket instead of relying on medical insurance.
Clinics order the product as appointment books fill, making consumer willingness to spend as important as doctor diagnosis. Repeat visits create recurring sales, but patients can choose Dysport, Xeomin or longer-lasting Daxxify. AbbVie must support injector training and dependable sterile supply while competing for each elective treatment.
SkyriziAbbVie's biggest medicine treats several chronic immune diseases. Sales grew about 24% year over year in Q2 2026; continued gains depend on health-plan access, reliable production and patent protection.AbbVie's biggest medicine treats several chronic immune diseases. Sales grew about 24% year over year in Q2 2026; continued gains depend on health-plan access, reliable production and patent protection.
In plain English
Think of Skyrizi as one tool fitted to several jobs. It quiets a particular part of the immune system that can drive psoriasis, Crohn's disease and ulcerative colitis, letting AbbVie sell the same medicine across several large groups of patients.
Doctors prescribe it, health plans decide how easily patients can get it, and repeat doses keep revenue coming. Adding diseases and easier ways to take the medicine brings in more patients, while rival treatments Tremfya and Omvoh compete for those new patients.
Competes with Tremfya (Johnson & Johnson) · Omvoh (Eli Lilly)
RinvoqA once-daily pill for several immune diseases, Rinvoq grew about 24% year over year in Q2 2026. Its reach is widening, but serious safety warnings, patient monitoring and health-plan rules shape use.A once-daily pill for several immune diseases, Rinvoq grew about 24% year over year in Q2 2026. Its reach is widening, but serious safety warnings, patient monitoring and health-plan rules shape use.
In plain English
This one is a daily tablet rather than a lab-made antibody. Rinvoq turns down immune signals behind arthritis, severe eczema and bowel inflammation, so one product can serve several diseases and compete with both pills and injected medicines.
AbbVie earns when doctors write prescriptions and patients refill them. The convenience of a pill helps, but the medicine carries serious safety warnings: doctors must decide who is suitable, monitor them, and work through health-plan restrictions. Cibinqo and Olumiant chase overlapping patients.
Competes with Cibinqo (Pfizer) · Olumiant (Eli Lilly/Incyte)
Apogee Therapeutics pipelineAbbVie paid $10.9B for long-lasting experimental immune medicines led by zumilokibart for severe eczema. There are no product sales yet; late-stage testing, approval and dependable manufacturing decide whether the purchase becomes a business.AbbVie paid $10.9B for long-lasting experimental immune medicines led by zumilokibart for severe eczema. There are no product sales yet; late-stage testing, approval and dependable manufacturing decide whether the purchase becomes a business.
In plain English
Here AbbVie paid upfront for a possible successor, not for current sales. Apogee's lead medicine is being tested as a longer-lasting treatment for severe eczema, while another candidate targets respiratory disease. Both are still experimental.
The idea is fewer doses and better control for patients, followed by repeat sales if regulators approve the medicines. Until then, money flows outward to trial sites and manufacturers. Approved medicines Ebglyss and Dupixent already set the standard that Apogee must beat or match in a useful way.
Competes with Ebglyss (Eli Lilly) · Dupixent (Sanofi/Regeneron)
Botox TherapeuticDoctor-administered Botox treats migraine, muscle tightness, bladder problems and other nerve-related conditions. Q2 2026 sales rose about 12%; growth relies on specialist use, insurance payment, trained injectors and sterile supply.Doctor-administered Botox treats migraine, muscle tightness, bladder problems and other nerve-related conditions. Q2 2026 sales rose about 12%; growth relies on specialist use, insurance payment, trained injectors and sterile supply.
In plain English
A familiar cosmetic name also does serious medical work. Carefully placed Botox injections calm overactive nerve signals, helping people with problems such as recurring migraine, stiff muscles and an overactive bladder.
Specialist clinics buy the medicine and administer it on a schedule; insurers often pay when the treatment is medically approved. That creates repeat orders tied to diagnosed patients and trained injectors. Dysport and Xeomin offer doctors similar toxin-based treatments, so coverage, results and reliable sterile production matter.
Competes with Dysport (Ipsen/Galderma) · Xeomin (Merz)
VraylarVraylar is a daily pill used for schizophrenia, bipolar disorder and alongside antidepressants. Sales grew about 19% year over year in Q2 2026; staying power rests on results, side effects and regular refills.Vraylar is a daily pill used for schizophrenia, bipolar disorder and alongside antidepressants. Sales grew about 19% year over year in Q2 2026; staying power rests on results, side effects and regular refills.
In plain English
For people living with serious mood or thought disorders, treatment is often a long routine rather than a one-time fix. Vraylar is a daily pill used across schizophrenia, bipolar disorder and depression when an antidepressant alone is not enough.
Each continuing prescription can become another refill, provided the medicine helps and its side effects remain manageable. Health plans influence access, and patients may switch among alternatives such as Caplyta and Rexulti. AbbVie sells Vraylar but pays the company that invented it, Gedeon Richter, a cut of those sales.
Competes with Caplyta (Johnson & Johnson) · Rexulti (Otsuka/Lundbeck)
Ubrelvy and Qulipta/AquiptaTwo oral migraine medicines divide the job: Ubrelvy treats an attack, while Qulipta aims to prevent one. Together they made $2.307B in FY2025; health-plan access and whether people keep taking them drive the next leg.Two oral migraine medicines divide the job: Ubrelvy treats an attack, while Qulipta aims to prevent one. Together they made $2.307B in FY2025; health-plan access and whether people keep taking them drive the next leg.
In plain English
Two pills divide one job. Ubrelvy is taken when a migraine attack arrives; Qulipta, called Aquipta in some countries, is taken to prevent attacks. That gives AbbVie a place in both the emergency cupboard and the daily routine.
Doctors prescribe them and health plans decide access, while repeat use turns relief and prevention into sales. The field is crowded: Nurtec can cover both immediate and preventive use, and Emgality is a longer-acting injection. AbbVie must keep patients on treatment, not merely win the first prescription.
Competes with Nurtec ODT (Pfizer) · Emgality (Eli Lilly)
HumiraOnce AbbVie's central product, Humira now competes with lower-cost, closely matched versions. Q2 2026 sales fell about 36%; its remaining job is to keep generating cash while newer immune medicines take over.Once AbbVie's central product, Humira now competes with lower-cost, closely matched versions. Q2 2026 sales fell about 36%; its remaining job is to keep generating cash while newer immune medicines take over.
In plain English
The former center of AbbVie is now a shrinking but still meaningful business. Humira is a self-injected medicine for arthritis, psoriasis, bowel disease and other conditions caused by an overactive immune system.
Its patents no longer keep close copies out of the United States. Health plans can favor those alternatives, and lower prices and substitution steadily pull prescriptions away. Existing patients and contracts still produce sales, but Amjevita and Cyltezo are built to serve the same uses. Humira's role has changed from growth engine to cash-producing bridge.
Competes with Amjevita (Amgen) · Cyltezo (Boehringer Ingelheim)
ImbruvicaImbruvica is a pill for certain blood cancers, but newer rivals are winning patients. Sales dropped about 29% year over year in Q2 2026, and AbbVie shares the medicine's U.S. profits with Janssen.Imbruvica is a pill for certain blood cancers, but newer rivals are winning patients. Sales dropped about 29% year over year in Q2 2026, and AbbVie shares the medicine's U.S. profits with Janssen.
In plain English
An early winner in blood-cancer pills is being overtaken. Imbruvica blocks a signal some cancer cells use to survive, and patients take it according to their disease and treatment plan. Newer medicines Calquence and Brukinsa now compete for many of the same people and have been gaining ground.
When the medicine sells, AbbVie does not keep all the money: Janssen controls sales outside the United States and the partners split U.S. profit and loss equally. Fewer new patients or shorter treatment therefore shrink both sales and the amount AbbVie ultimately keeps.
Competes with Calquence (AstraZeneca) · Brukinsa (BeOne Medicines)
Venclexta/VenclyxtoVenclexta blocks a survival switch used by certain leukemia cells and remains AbbVie's growing cancer counterweight. Q2 2026 sales rose about 10%; treatment combinations and the profit-sharing deal determine what AbbVie keeps.Venclexta blocks a survival switch used by certain leukemia cells and remains AbbVie's growing cancer counterweight. Q2 2026 sales rose about 10%; treatment combinations and the profit-sharing deal determine what AbbVie keeps.
In plain English
Cancer cells can lean on an internal survival switch; Venclexta is a pill designed to block it. Doctors use the medicine for certain leukemias, sometimes alongside other treatments, and the length and mix of those treatment plans create demand.
AbbVie makes and distributes the drug, while Genentech and Roche share half of U.S. profit before tax. That means rising sales do not all stay with AbbVie. Lisaftoclax targets the same switch, while Calquence offers another route for some of the same leukemia patients.
Competes with Lisaftoclax (Ascentage Pharma) · Calquence (AstraZeneca)
Botox CosmeticBotox Cosmetic is the out-of-pocket side of the toxin franchise, sold through trained cosmetic injectors. Q2 2026 sales grew about 3%; demand is more exposed to consumer budgets and rival claims about duration.Botox Cosmetic is the out-of-pocket side of the toxin franchise, sold through trained cosmetic injectors. Q2 2026 sales grew about 3%; demand is more exposed to consumer budgets and rival claims about duration.
In plain English
This side of Botox is bought for appearance rather than illness. Trained injectors use small doses in facial-aesthetic procedures, and customers usually pay out of pocket instead of relying on medical insurance.
Clinics order the product as appointment books fill, making consumer willingness to spend as important as doctor diagnosis. Repeat visits create recurring sales, but patients can choose Dysport, Xeomin or longer-lasting Daxxify. AbbVie must support injector training and dependable sterile supply while competing for each elective treatment.
Competes with Dysport (Ipsen/Galderma) · Xeomin (Merz) · Daxxify (Crown Laboratories/Revance)
Named in filings, launches and programs
- Eye Care portfolioProduct lineA collection of prescription and consumer eye treatments that produced $2.109B in FY2025 across several brands.
- CreonProductA U.S.-only digestive-enzyme medicine for people whose pancreas does not release enough enzymes; FY2025 sales were $1.512B.
- Mavyret/MaviretProductAn oral hepatitis C cure franchise that generated $1.317B in FY2025.
- Other Aesthetics portfolioProduct lineSkinMedica, AlloDerm, Natrelle, Latisse and DiamondGlow extend the aesthetics business beyond injections.
- Elahere, Epkinly/Tepkinly and EmrelisProduct line · RampingNewer cancer medicines beginning to refresh a portfolio still weighed down by Imbruvica's decline.
- Juvederm CollectionBrandFacial fillers sold to aesthetics injectors; the collection brought in $993M in FY2025.
- Linzess/ConstellaProductA constipation and irritable-bowel medicine with $907M of FY2025 sales.
- Vyalev/Produodopa and Duodopa/DuopaProduct line · RampingContinuous delivery treatments for advanced Parkinson's disease, together producing $863M in FY2025.
- Other NeuroscienceProduct lineSmaller brain and nerve medicines outside the named franchises contributed $207M in FY2025.
- Etentamig and partnered oncology pipelineProduct · Pre-revenueExperimental blood-cancer and solid-tumor medicines intended to rebuild the cancer portfolio beyond Imbruvica.
- Capstan, Nimble, Gubra and Gilgamesh platformsProduct · Pre-revenueAcquired experimental programs span immune-cell treatment, oral protein-like medicines, weight control and brain disorders; none yet contributes product sales.
Eye Care portfolioProduct line
A collection of prescription and consumer eye treatments that produced $2.109B in FY2025 across several brands.
CreonProduct
A U.S.-only digestive-enzyme medicine for people whose pancreas does not release enough enzymes; FY2025 sales were $1.512B.
Mavyret/MaviretProduct
An oral hepatitis C cure franchise that generated $1.317B in FY2025.
Other Aesthetics portfolioProduct line
SkinMedica, AlloDerm, Natrelle, Latisse and DiamondGlow extend the aesthetics business beyond injections.
Elahere, Epkinly/Tepkinly and EmrelisProduct line · Ramping
Newer cancer medicines beginning to refresh a portfolio still weighed down by Imbruvica's decline.
Juvederm CollectionBrand
Facial fillers sold to aesthetics injectors; the collection brought in $993M in FY2025.
Linzess/ConstellaProduct
A constipation and irritable-bowel medicine with $907M of FY2025 sales.
Vyalev/Produodopa and Duodopa/DuopaProduct line · Ramping
Continuous delivery treatments for advanced Parkinson's disease, together producing $863M in FY2025.
Other NeuroscienceProduct line
Smaller brain and nerve medicines outside the named franchises contributed $207M in FY2025.
Etentamig and partnered oncology pipelineProduct · Pre-revenue
Experimental blood-cancer and solid-tumor medicines intended to rebuild the cancer portfolio beyond Imbruvica.
Capstan, Nimble, Gubra and Gilgamesh platformsProduct · Pre-revenue
Acquired experimental programs span immune-cell treatment, oral protein-like medicines, weight control and brain disorders; none yet contributes product sales.